NCT01758289

Post Marketing Observational Study on Paricalcitol IV Administered to Venezuelan Patients

A Prospective, Multicenter, Six-Month Study on the Effectiveness, Safety and Impact on Health Related Quality of Life (HRQoL) and Depression Symptoms of Paricalcitol Administered to Venezuelan Patients With Chronic Kidney Disease (Stage V) Who Are on Hemodialysis

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 105 (actual)
• Sponsor: AbbVie (prior sponsor, Abbott) · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study was designed to evaluate the effectiveness, safety, and impact on quality of life when paricalcitol (Zemplar® intravenous \[IV\]) is administered in Venezuelan patients on hemodialysis who are at risk of developing secondary hyperparathyroidism associated with stage V chronic kidney disease.

Conditions

• Chronic Kidney Disease Stage V
• Hemodialysis

Timeline

• Start date: 2013-01-01
• Primary completion: 2013-11-01
• Completion: 2013-11-01
• First posted: 2013-01-01
• Last updated: 2014-11-17
• Results posted: 2014-11-17

Locations

8 sites across 1 country: Venezuela